Over the last 7 days, the United States market has experienced a 2.5% decline, though it has seen a significant rise of 23% over the past year, with earnings projected to grow by 17% annually. In this context, identifying stocks that are estimated to be trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on undervalued assets in an evolving market landscape.

Top 10 Undervalued Stocks Based On Cash Flows In The United States

Name	Current Price	Fair Value (Est)	Discount (Est)
Solstice Advanced Materials (SOLS)	$81.02	$156.32	48.2%
Robert Half (RHI)	$31.26	$60.09	48%
Rayonier (RYN)	$20.97	$40.79	48.6%
MercadoLibre (MELI)	$1607.80	$3085.44	47.9%
Live Oak Bancshares (LOB)	$37.41	$74.21	49.6%
Lazard (LAZ)	$46.36	$91.21	49.2%
Inter & Co (INTR)	$5.67	$10.91	48%
Cactus (WHD)	$56.62	$111.45	49.2%
BlackSky Technology (BKSY)	$34.76	$68.23	49.1%
AbbVie (ABBV)	$227.23	$444.25	48.9%

Here's a peek at a few of the choices from the screener.

RadNet (RDNT)

Overview: RadNet, Inc., along with its subsidiaries, offers outpatient diagnostic imaging services both in the United States and internationally, with a market cap of approximately $4.27 billion.

Operations: The company's revenue is primarily derived from its Imaging Centers segment, contributing $2.08 billion, followed by the Digital Health segment at $102.59 million.

Estimated Discount To Fair Value: 39.4%

RadNet is trading at US$54.34, significantly below its estimated future cash flow value of US$89.74, indicating potential undervaluation based on discounted cash flow analysis. Despite a net loss of US$33.47 million in Q1 2026, RadNet's earnings are forecast to grow substantially at 86.55% annually as it seeks strategic growth through acquisitions and partnerships like the recent joint venture with Saint Alphonsus Health System, which could enhance revenue streams and operational efficiencies.

Merck (MRK)

Overview: Merck & Co., Inc. is a global healthcare company with operations spanning pharmaceuticals, vaccines, and animal health, and it has a market cap of approximately $298.33 billion.

Operations: The company's revenue segments include $58.85 billion from pharmaceuticals and $6.56 billion from animal health.

Estimated Discount To Fair Value: 47.2%

Merck is trading at US$120.79, significantly below its estimated future cash flow value of US$228.62, suggesting undervaluation based on discounted cash flow analysis. Despite a recent decline in profit margins and high debt levels, Merck's earnings are forecast to grow significantly at 21.21% annually over the next three years. Recent FDA Breakthrough Therapy designation for calderasib could enhance Merck's oncology portfolio, potentially boosting future cash flows and offsetting current financial challenges.

Rush Street Interactive (RSI)

Overview: Rush Street Interactive, Inc. operates as an online casino and sports betting company across the United States, Canada, and Latin America with a market cap of $6.08 billion.

Operations: The company generates revenue primarily through its online gaming and retail sports betting segment, which totaled $1.24 billion.

Estimated Discount To Fair Value: 24.4%

Rush Street Interactive is trading at US$26.14, notably below its estimated future cash flow value of US$34.57, indicating it may be undervalued based on discounted cash flow analysis. Despite slower revenue growth forecasts compared to the market, earnings are expected to grow significantly at 32.4% annually over the next three years. Recent share repurchase and equity offerings could impact stock valuation positively by enhancing shareholder value and providing additional capital for growth initiatives.

Where To Now?

• Embark on your investment journey to our 140 Undervalued US Stocks Based On Cash Flows selection here.
• Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
• Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Interested In Other Possibilities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.